IDT Acquires GenBase to Establish New Oligo Production Capability
News Dec 16, 2005
The acquisition, which results in the establishment of a new IDT West Coast Operations division, gives the company an immediate, locally based, next-day oligo production capability in the heart of the California biotech industry, as well as access to GenBase's local knowledge and industry experience.
"Researchers everywhere are under pressure to produce results quickly, and they know that IDT represents the best in oligo synthesis, quality assurance, and customer support," noted Trey Martin, chief operating officer of Integrated DNA Technologies, Inc.
"Now we're bringing that quality standard and QC to the next-day service sector at the heart of California's important oligo market."
"GenBase's success in serving organizations for the last eight years played a central role in the development of this deal," said Jun Wang, founder and CEO of GenBase, Inc.
"We share IDT's commitment to the customer, and to the Life Sciences industry, and look forward to adding our experience, and ideas to theirs."
Heading IDT's West Coast Operations in San Diego will be general manager Dan Dernbach, an eight year veteran at IDT.
GenBase's Jun Wang will remain as IDT's vice-president of international sales, with a focus on the Pacific Rim.
The new facility will use Integrated DNA Technologies' in-house nucleic acid synthesis technologies and processes, and will begin oligonucleotide production in late December 2005.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.